drugset / Trial / NCT05444257

A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy

NCT05444257

Phase 3 Active not recruiting 822 enrolled Vertex Pharmaceuticals Incorporated
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of VX-121/tezacaftor/deutivacaftor (VX-121/TEZ/D-IVA) in participants with cystic fibrosis.

Timeline

Start
2022-11-08
Primary completion
2026-10-30
Completion
2026-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Vanzacaftor Small molecule Oral
Subject deutivacaftor Unknown Oral
Subject tezacaftor Other / unclassified Oral

Indications